Cost Effectiveness. The Engineer shall evaluate cost-effectiveness to determine if the improvements cause sufficient user benefits to justify the DocuSign Envelope ID: D3D386F2-9BB1-46C4-A6B5-298DBCC339A1 DocuSign Envelope ID: 289281F7-43A6-4F0C-BC8B-BFB572B13384 Contract No. 36-6IDP5376 PeopleSoft Contract No. 5675 investment. The Engineer shall evaluate cost-effectiveness by determining the benefits (dollar-value) associated with the reduction in vehicle delay due to a short-term improvement and comparing the benefit to the cost of implementing the improvement. Benefits shall be determined using the results of the peak hour model and converting the hourly delay values to estimated daily and annual delays, which shall then be multiplied by an average cost per hour of delay to achieve annual benefits (dollar-value).
Cost Effectiveness. Notwithstanding that the Cost Estimate anticipates a greater cost for any item or improvement, each Party shall endeavor in good faith to administer the Prime Agreements (as defined below) to which it is a party in a manner intended to result in the most cost effective construction and delivery of services considering all factors including the life cycle and functionality of the subject improvements.
Cost Effectiveness. The Agency shall ensure that the Health Plan is cost-effective (see s. 409.912(42), F.S.). The Agency may not renew this Contract if it is not cost-effective.
Cost Effectiveness. For the purposes of this article 5, all assessments of cost effectiveness are subject to Schedule D.
Cost Effectiveness. The Companies agree to present joint Total Resource Cost (“TRC”) and Program Administrator Cost test (“PACT”) results for each program and each portfolio as part of its 2022- 2025 Plan filing and any ex-post cost effectiveness reporting. Results will be combined gas/electric results for programs saving both fuels. Results will include benefit-cost ratios as well as the net present value (“NPV”) of benefits, costs and net benefits for the following scenarios: with and without non-energy impacts (“XXXx”) (if available at the time of evaluation), as well as, at the portfolio-level TRC, with and without income qualified programs. To the extent there are delays in receiving the joint program cost-effectiveness details from other utilities, The Companies may file the joint TRC and PACT test results after the initial Plan filing, but no later than April 15, 2021. To the extent there are delays in receiving the joint program cost- effectiveness details from other utilities, the Companies may file the joint TRC and PAC test results after the initial Plan filing, but no later than April 15, 2021.
Cost Effectiveness. The Parties expect that actions will be cost-effective, feasible and based on the best available science, to achieve the goals and objectives of the Action Plan. The Parties will be fiscally prudent and adhere to approved budgets.
Cost Effectiveness. The Agency shall ensure that the Health Plan is cost-effective (see s. 409.912(44), F.S.). The Agency may not renew this Contract if it is not cost-effective. WellCare of Florida, Inc. d/b/a Staywell Health Plan of Florida Medicaid HMO Non-Reform Contract WellCare of Florida, Inc. d/b/a Staywell Health Plan of Florida Medicaid HMO Non-Reform Contract ATTACHMENT II
Cost Effectiveness. Because of our utilization of experienced professionals, we are capable of providing services efficiently without sacrificing quality. We have competitively priced our proposal using staff assignments that we believe to be the most efficient and effective based on our firsthand experience performing various types of claims audits. Our rates reflect the unsurpassed quality of the specialized staff members who we recruit, train, retain, and continually educate in order to provide the Department with the best service possible.
Cost Effectiveness. The Management Committee will be responsible for reviewing the cost-effectiveness of the supply of each Product and to determine the amount of the manufacturing costs of each Collaborator that will be permitted as an Allowable Expense. [CONFIDENTIAL TREATMENT REQUESTED] In reviewing the cost-effectiveness of the supply of each Product, the Management Committee may compare the Costs of manufacturing a Product at the Chiron Facility and at the Cephalon Facility. If the per unit cost of manufacturing a Product is higher at one of these facilities, the Management Committee shall review the cost-effectiveness of such manufacturing and shall determine the amount of the manufacturing costs that will be permitted as an Allowable Expense; provided, however, that in considering the cost- effectiveness of the manufacturing and the Costs permitted as Allowable Expenses, the Management Committee shall recognize that a reasonable difference in the costs of manufacturing at the Chiron Facility and the Cephalon Facility is to be expected in relation to the costs and benefits of maintaining an Alternative Facility, and is permitted as an Allowable Expense.
Cost Effectiveness. While not the only purpose of the evaluation, the core purpose of the evaluation is to support a determination as to whether the preponderance of the evidence about the costs and effectiveness of the demonstration when considered in its totality demonstrates cost effectiveness taking into account both initial and longer term costs and other impacts such as improvements in service delivery and health outcomes.
i. The evaluation will explore and explain through developed evidence the effectiveness of the demonstration for each hypothesis, including total costs in accordance with the evaluation design as approved by CMS. Included in the evaluation will be examinations using a robust set of measures of provider access and clinical quality measures under the demonstration compared to what would have happened for a comparable population absent the demonstration.
ii. The state will compare total costs under the demonstration to costs of what would have happened without the demonstration. This will include an evaluation of provider rates, healthcare utilization and associated costs, and administrative expenses over time.
iii. The State will compare changes in access and quality to associated changes in costs within the demonstration. To the extent possible, component contributions to changes in access and quality and their associated levels of investment will be determined and compared to improvement efforts undertaken in other delivery systems.
